首页> 外文期刊>Journal of clinical apheresis. >Recruitment of immature neutrophils in peripheral blood following leukocytapheresis therapy for rheumatoid arthritis.
【24h】

Recruitment of immature neutrophils in peripheral blood following leukocytapheresis therapy for rheumatoid arthritis.

机译:类风湿关节炎的白细胞去除疗法后,外周血中未成熟的中性粒细胞的募集。

获取原文
获取原文并翻译 | 示例
       

摘要

The objective of this study is to evaluate the cellular mechanism underlying filtration leukocytapheresis (LCAP) therapy for the treatment of rheumatoid arthritis (RA). Thirteen patients with refractory RA each underwent three sessions of LCAP. Before (pre-) and after (post-) the completion of the first LCAP session, peripheral blood was sampled and analyzed for neutrophil surface markers using flow cytometry. The surface antigens of peripheral blood mononuclear cells (PBMCs) and neutrophils obtained at pre- and post-LCAP were then analyzed using a fluorescence-activated cell sorter. The American College of Rheumatology's criterion of a 20% improvement was achieved in six patients, but not in the other seven patients, after LCAP therapy. The post-LCAP number of blood band form neutrophils with a bone marrow phenotype (CD49d(dim+), low density) was higher among the responders than among the nonresponders, suggesting an association between the clinical response and the recruitment of bone-marrow-derived neutrophils. After the nonspecific absorption of WBCs during a 1-h Cellsorba procedure, the number of PBMCs was consistently decreased, although the number of neutrophils that were affected by removal plus recruitment varied in a manner that was independent of efficacy. In contrast, the emergence of immature neutrophils in the peripheral blood was characteristic of the effective therapies. These cells were found after the 1st session of responders and also found following sessions of LCAPs. Immature neutrophils, which may be recruited from the bone marrow in the peripheral blood after the first session of LCAP, can predict the clinical efficacy of subsequent LCAP sessions.
机译:这项研究的目的是评估过滤性白细胞减少症(LCAP)治疗类风湿关节炎(RA)的细胞机制。 13名难治性RA患者均接受了3次LCAP治疗。在第一个LCAP会话完成之前(之前)和之后(之后),对外周血进行采样并使用流式细胞仪分析中性粒细胞表面标志物。然后使用荧光激活细胞分选仪分析在LCAP之前和之后获得的外周血单核细胞(PBMC)和嗜中性粒细胞的表面抗原。 LCAP治疗后,有6位患者达到了美国风湿病学会提高20%的标准,而其他7位患者则没有。应答者中具有骨髓表型(CD49d(dim +),低密度)的带状中性粒细胞的LCAP后数目高于未应答者,表明临床应答与骨髓来源募集之间的关联中性粒细胞。在1h Cellsorba程序中非特异性吸收WBC之后,PBMC的数量持续减少,尽管受去除和募集影响的中性粒细胞的数量以独立于功效的方式变化。相反,外周血中未成熟的中性粒细胞的出现是有效疗法的特征。这些细胞是在第一次应答后发现的,在LCAP之后也发现了。不成熟的中性粒细胞可能在第一次LCAP疗程后从外周血中的骨髓中募集,可以预测后续LCAP疗程的临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号